Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

The 2022 Tandem Meetings | Peripheral blood vs bone marrow stem cells for alloHSCT & optimal CD34+ graft cell dose

Muhammad Umair Mushtaq • 25 Apr 2022

The 2022 Tandem Meetings

General

Muhammad Umair Mushtaq, MD, University of Kansas Medical Center, Westwood, KS, compares the different cell sources for allogeneic hematopoietic stem cell transplantation (alloHSCT), and discusses the optimal CD34+ graft cell dose. Dr Ushtaq explains that it is possible to control the amount of CD34+ cells collected from the peripheral blood but not from the bone marrow. In a recent meta-analysis, it was shown that the ideal CD34+ graft cell dose is between 4-6×10⁶/kg, but it is necessary to perform a registry study to better define this value. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Outcomes of HLA-matched unrelated donor versus haploidentical transplantation

Muhammad Umair Mushtaq • 17 Feb 2023

Outcomes with CD34-selected stem cell boost for poor graft function and graft failure after alloSCT

Muhammad Umair Mushtaq • 17 Feb 2023

Continuous IVIG and platelet transfusion for refractory AITP in patients undergoing alloSCT

Muhammad Umair Mushtaq • 17 Feb 2023

Immunogenicity of COVID-19 vaccination in transplant and CAR-T therapy recipients

Muhammad Umair Mushtaq • 25 Apr 2022

Related Videos

The difficulty in developing predictive potency assays

Valentin Ortiz-Maldonado • 16 Apr 2024

Personalized risk assessment for transplantation in primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024

Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024

Hematological manifestations associated with primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024